Embryonic transcription factor SOX9 drives breast cancer endocrine resistance

The estrogen receptor (ER) drives the growth of most luminal breast cancers and is the primary target of endocrine therapy. Although ER blockade with drugs such as tamoxifen is very effective, a major clinical limitation is the development of endocrine resistance especially in the setting of metasta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Proc Natl Acad Sci U S A
Main Authors: Jeselsohn, Rinath, Cornwell, MacIntosh, Pun, Matthew, Buchwalter, Gilles, Nguyen, Mai, Bango, Clyde, Huang, Ying, Kuang, Yanan, Paweletz, Cloud, Fu, Xiaoyong, Nardone, Agostina, De Angelis, Carmine, Detre, Simone, Dodson, Andrew, Mohammed, Hisham, Carroll, Jason S., Bowden, Michaela, Rao, Prakash, Long, Henry W., Li, Fugen, Dowsett, Mitchell, Schiff, Rachel, Brown, Myles
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2017
Assuntos:
PNAS Plus
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5465894/
https://ncbi.nlm.nih.gov/pubmed/28507152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1620993114
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados